RUS MED Exports Pvt. Ltd. Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: RUS MED Exports Pvt. Ltd. Pharmaceutical Export Portfolio Dataset — 4 Products, $483.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

RUS MED Exports Pvt. Ltd. — Pharmaceutical Exporter Profile (2026) | 4 Products, $483.6K Trade | TransData Nexus

RUS MED Exports Pvt. Ltd.

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $483.6K Total Trade · DGFT Verified

RUS MED Exports Pvt. Ltd. is an Indian pharmaceutical exporter with a total trade value of $483.6K across 4 products in 2 therapeutic categories. Based on 29 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cytarabine ($311.9K), Pemetrexed ($88.3K), Etoposide ($48.0K).

RUS MED Exports Pvt. Ltd. — Export Portfolio & Destination Treemap

RUS MED Exports Pvt. Ltd. pharmaceutical export portfolio — 4 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is RUS MED Exports Pvt. Ltd.? — Company Overview & Market Position

RUS MED Exports Pvt. Ltd. is an Indian pharmaceutical exporter established in 2004, headquartered in Mumbai, Maharashtra. The company is privately held, with a Corporate Identification Number (CIN) of U51509MH2004PTC146939. Its registered office is located at A-503/504, Remi Bizcourt, Shah Industrial Estate, Off Veera Desai Road, Andheri (W), Mumbai-400053. The company specializes in exporting high-quality oncology generic medicines, primarily targeting markets in Russia and the Commonwealth of Independent States (CIS).

As of the latest available data, RUS MED Exports Pvt. Ltd. has a total export value of $484,000 USD, with 29 shipments across four products in two therapeutic categories. The company's top five products include Cytarabine ($312,000), Pemetrexed ($88,000), Etoposide ($48,000), and Dacarbazine ($35,000). The primary therapeutic focus is on advanced oncology, accounting for 90.1% of the portfolio, with oncology comprising the remaining 9.9%. The company's product portfolio is highly concentrated, with the top five products representing 100% of its exports.

What Does RUS MED Exports Pvt. Ltd. Export? — Product Portfolio Analysis

Top Products by Export Value

1Cytarabine$311.9K

Product Portfolio — Top 4 by Export Value

RUS MED Exports Pvt. Ltd. exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cytarabine	Advanced Oncology	$311.9K	16	2.9%	6
2	Pemetrexed	Advanced Oncology	$88.3K	5	0.3%	15
3	Etoposide	Oncology	$48.0K	3	0.4%	14
4	Dacarbazine	Advanced Oncology	$35.4K	5	2.5%	11

RUS MED Exports Pvt. Ltd. exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $483.6K. The top category is Advanced Oncology (90.1% of portfolio), followed by Oncology (9.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

RUS MED Exports Pvt. Ltd. — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

RUS MED Exports Pvt. Ltd. does not own manufacturing facilities; instead, it collaborates with third-party manufacturers to produce its pharmaceutical products. This strategy allows the company to maintain flexibility and focus on its core competencies in marketing and distribution. The company emphasizes stringent quality control measures and on-time delivery, ensuring that all products meet the highest standards of safety and efficacy.

3Key Leadership

The leadership team at RUS MED Exports Pvt. Ltd. is headed by Dr. Ulhas Jayant Vasave, a medical doctor with over 20 years of experience in clinical medicine and public health. Dr. Vasave completed his MBBS from T. N. Medical College, Mumbai, and holds a Masters in Public Health from SRM University Chennai. He has been trained in the Epidemic Intelligence Service by the CDC-US and NCDC-India. His extensive background includes working with tertiary care hospitals, international organizations, and the Public Health Department of the Government of Maharashtra.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does RUS MED Exports Pvt. Ltd. Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

RUS MED Exports Pvt. Ltd. primarily exports its pharmaceutical products to Russia, with a total export value of $491,490 USD in 2025. The company's export activities are concentrated in this market, indicating a strategic focus on meeting the demand for oncology medications in Russia.

2Emerging Markets

RUS MED Exports Pvt. Ltd. has not been reported to have significant export activities in emerging markets such as Africa, Latin America, or Southeast Asia. The company's export data indicates a primary focus on Russia, with no substantial shipments recorded to other regions.

3Geographic Strategy

The company's export strategy is highly concentrated, with 100% of its exports directed towards Russia. This focus on a single market may expose the company to risks associated with geopolitical changes, regulatory shifts, and market dynamics within Russia. Diversifying its export destinations could mitigate these risks and open new avenues for growth.

RUS MED Exports Pvt. Ltd. — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information indicating that RUS MED Exports Pvt. Ltd. has FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or a history of FDA inspections. The company's export activities are primarily focused on Russia, and it does not appear to have a significant presence in the U.S. market.

2WHO & EU GMP

RUS MED Exports Pvt. Ltd. has not been reported to hold WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The company's export data indicates a focus on the Russian market, and there is no evidence of its products being marketed in regions requiring WHO or EU GMP certifications.

3CDSCO & Indian Regulatory

RUS MED Exports Pvt. Ltd. holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained necessary approvals from state drug controllers for its export activities. The company complies with Indian regulatory requirements for the export of pharmaceutical products.

RUS MED Exports Pvt. Ltd. — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

RUS MED Exports Pvt. Ltd. operates in a competitive landscape with several key players in the oncology generic medicines export sector. While specific market share data is not available, the company's focus on the Russian market places it in competition with other pharmaceutical exporters targeting the same region. The company's emphasis on quality and on-time delivery serves as a competitive advantage in this market.

2Key Differentiators

RUS MED Exports Pvt. Ltd. differentiates itself through its specialized focus on oncology generic medicines, leveraging its founders' pharmaceutical background to ensure high-quality products. The company's commitment to on-time delivery and adherence to stringent safety and efficacy standards further distinguishes it in the market.

3Strategic Position

RUS MED Exports Pvt. Ltd. currently focuses on exporting generic oncology medications, primarily to Russia. The company's strategic direction appears to be centered on meeting the specific needs of the Russian market. Exploring opportunities in other therapeutic areas and diversifying its export destinations could provide avenues for future growth.

Buyer Due Diligence Brief — Evaluating RUS MED Exports Pvt. Ltd. as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

RUS MED Exports Pvt. Ltd. collaborates with third-party manufacturers to produce its pharmaceutical products. The company's export data indicates a consistent volume of shipments, primarily to Russia, suggesting a reliable supply chain. However, the lack of diversification in export destinations may limit the company's ability to mitigate risks associated with over-reliance on a single market.

2Certifications to Verify

Importers should verify the following certifications when considering RUS MED Exports Pvt. Ltd. as a supplier:

FDA Facility Registration: To confirm compliance with U.S. regulatory standards.

WHO-GMP Certification: To ensure adherence to international manufacturing practices.

EU GMP Certification: To verify compliance with European manufacturing standards.

Frequently Asked Questions — RUS MED Exports Pvt. Ltd.

How many pharmaceutical products does RUS MED Exports Pvt. Ltd. export from India?

RUS MED Exports Pvt. Ltd. exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Cytarabine ($311.9K), Pemetrexed ($88.3K), Etoposide ($48.0K), Dacarbazine ($35.4K). Total export value is $483.6K.

What is RUS MED Exports Pvt. Ltd.'s total pharmaceutical export value?

RUS MED Exports Pvt. Ltd.'s total pharmaceutical export value is $483.6K, based on 29 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does RUS MED Exports Pvt. Ltd. cover?

RUS MED Exports Pvt. Ltd. exports across 2 therapeutic categories. The largest are Advanced Oncology (90.1%, 3 products), Oncology (9.9%, 1 products).

Get Full RUS MED Exports Pvt. Ltd. Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.